Klotho Neurosciences launched two genomics-based assays on March 10, 2026, designed to measure biological age—how fast your cells are aging—in patients enrolling in neurodegenerative disease trials. The company's "Klotho Clock" combines DNA analysis with messenger RNA profiling across nine genes linked to longevity, aiming to balance clinical trial groups by cellular health rather than birthdate alone.

Why does biological age matter in trials? Because mismatches between trial groups can hide whether a drug actually works. Two 65-year-olds may have the same number of birthdays, but their cells may be aging at very different rates. In Alzheimer's and ALS studies, participants of identical calendar age may have sharply different rates of cellular decline. When placebo groups happen to be biologically younger—healthier at the cellular level—even effective therapies may fail to show a measurable benefit.

Klotho's tests seek to prevent that imbalance by measuring epigenetic markers—chemical tags on DNA that accumulate as cells age and can silence important genes.

How the stratification works: Higher levels of these chemical tags at the KLOTHO gene correlate with accelerated aging, a relationship confirmed across multiple studies. By assigning patients with similar tagging patterns to treatment and placebo groups, researchers reduce hidden variation in trial populations. That sharpens the statistical power and can lower the number of volunteers needed to detect real drug effects.

In neurodegenerative trials, where disease progression is slow and dropout rates high, that efficiency could cut costs and shorten timelines by months.

The first assay analyzes cell-free DNA from a blood sample to measure chemical tagging at the KLOTHO gene; the second adds counts of active gene copies and uses artificial intelligence to analyze genetic variants across the nine-gene panel. Dr. Bret Barnes, former Illumina genomics lead, said the company designed its tests to account for natural human genetic variation, aiming to improve accuracy and reduce sequencing costs.

The science is promising but unproven: No peer-reviewed validation of the proprietary Klotho Clock exists as of March 2026. A registered trial (NCT07216781) lists epigenetic age as a baseline outcome measure, but performance metrics—such as sample size, error margins, reproducibility, and cost per test—remain undisclosed. The assay's classification as emerging science means independent confirmation is needed before it can guide high-stakes enrollment decisions.

U.S. regulators are still developing guidelines for these tools. The FDA has cleared DNA methylation tests for cancer diagnosis but has not yet approved aging clocks for therapeutic trial stratification. NIH aging research programs, including the Geroscience Initiative, are actively investigating whether epigenetic markers can predict disease trajectory, signaling federal interest but no formal guidance yet.

Klotho plans to use the tests in its own gene-therapy trials and offer them to outside trial sponsors seeking sharper patient selection. Independent validation, regulatory clearance, and transparent data-privacy safeguards will determine whether the clock becomes a standard research tool. The NCT07216781 trial will report baseline epigenetic age data in Q3 2026, offering the first public window into how well the assay performs against calendar age and clinical progression measures—a key test of whether biological age clocks can deliver on their promise.